Meet the Second Round of Drugs Facing Medicare Price Negotiation
-
Jan 23, 2025
The popular blockbuster diabetes and weight loss drugs — Ozempic and Wegovy — are among the 15 drugs selected for the second round of Medicare drug price negotiations as part of the Inflation Reduction Act, according to CMS. The negotiated prices will go into effect in 2027.
The 15 selected drugs were used by more than 5.2 million Medicare Part D beneficiaries and accounted for about $40.7 billion in total Medicare Part D gross spending between Nov. 1, 2023, and Oct. 31, 2024. Combined with the first 10 drugs already negotiated by Medicare, they represent over a third of total gross spending under Medicare Part D, CMS reported.
Read more
© 2024 MMIT
Related Posts
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.